{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:56:08Z","timestamp":1792691768572,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002338","name":"Ministry of Education of the People's Republic of China","doi-asserted-by":"publisher","award":["JYB2025XDXM601"],"award-info":[{"award-number":["JYB2025XDXM601"]}],"id":[{"id":"10.13039\/501100002338","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bioorg.2026.110204","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T15:09:53Z","timestamp":1783177793000},"page":"110204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Potent and isoform-selective PARP1 degraders for the treatment of BRCA-deficient cancers"],"prefix":"10.1016","volume":"180","author":[{"given":"Hui","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongrong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.110204_bb0005","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/s41419-025-08235-2","article-title":"The breakome of BRCA1 and BRCA2 pathway mutation carriers reveals early processes in breast oncogenesis","volume":"16","author":"Oster Flayshman","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bioorg.2026.110204_bb0010","first-page":"189","article-title":"Chromosomal instability as enabling feature and central hallmark of breast cancer","volume":"15","author":"Castellanos","year":"2023","journal-title":"Breast Cancer: Targets Ther."},{"key":"10.1016\/j.bioorg.2026.110204_bb0015","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13046-021-02005-6","article-title":"PARP inhibitors in gastric cancer: beacon of hope","volume":"40","author":"Wang","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110204_bb0020","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.tibs.2023.11.001","article-title":"Causes and consequences of DNA single-strand breaks","volume":"49","author":"Caldecott","year":"2024","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.bioorg.2026.110204_bb0025","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0092-8674(03)00433-1","article-title":"PARP goes transcription","volume":"113","author":"Kraus","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2026.110204_bb0030","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.cell.2011.03.041","article-title":"Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11","volume":"145","author":"Schlacher","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2026.110204_bb0035","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ccr.2012.05.015","article-title":"A distinct replication fork protection pathway connects fanconi anemia tumor suppressors to RAD51-BRCA1\/2","volume":"22","author":"Schlacher","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2026.110204_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2022.100049","article-title":"Homologous recombination repair deficiency: an overview for pathologists","volume":"36","author":"Doig","year":"2023","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.bioorg.2026.110204_bb0045","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.3390\/cancers15143642","article-title":"Mechanisms of PARP-inhibitor-resistance in BRCA-mutated breast cancer and new therapeutic approaches","volume":"15","author":"Dilmac","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2026.110204_bb0050","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.3390\/cancers15082357","article-title":"PARP inhibitors in breast and ovarian cancer","volume":"15","author":"Wang","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2026.110204_bb0055","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S1097-2765(00)80202-6","article-title":"Brca1 controls homology-directed DNA repair","volume":"4","author":"Moynahan","year":"1999","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bioorg.2026.110204_bb0060","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.110204_bb0065","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.110204_bb0070","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2026.110204_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.108058","article-title":"Poly (ADP-ribose) polymerase (PARP) inhibitors approved for the treatment of cancer","volume":"222","author":"Roskoski","year":"2025","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2026.110204_bb0080","first-page":"471","article-title":"PARP inhibitors in ovarian cancer: a review, targeted","volume":"18","author":"O\u2019Malley","year":"2023","journal-title":"Oncol"},{"key":"10.1016\/j.bioorg.2026.110204_bb0085","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/cas.13947","article-title":"Pharmacologic characterization of fluzoparib, a novel poly(ADP -ribose) polymerase inhibitor undergoing clinical trials","volume":"110","author":"Wang","year":"2019","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bioorg.2026.110204_bb0090","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41591-023-02704-x","article-title":"First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial","volume":"30","author":"Fizazi","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioorg.2026.110204_bb0095","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1158\/1078-0432.CCR-21-1186","article-title":"Pamiparib monotherapy for patients with germline BRCA1\/2 -mutated ovarian cancer previously treated with at least two lines of chemotherapy: a multicenter, open-label, phase II study","volume":"28","author":"Wu","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110204_bb0100","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1038\/s41591-024-03003-9","article-title":"Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial","volume":"30","author":"Wu","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioorg.2026.110204_bb0105","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/nature06548","article-title":"Resistance to therapy caused by intragenic deletion in BRCA2","volume":"451","author":"Edwards","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.110204_bb0110","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1016\/j.celrep.2016.05.031","article-title":"FANCD2 maintains fork stability in BRCA1\/2-deficient tumors and promotes alternative end-joining DNA repair","volume":"15","author":"Kais","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.bioorg.2026.110204_bb0115","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/bjc.2016.203","article-title":"ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells","volume":"115","author":"Vaidyanathan","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2026.110204_bb0120","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.ccell.2019.05.012","article-title":"Selective loss of PARG restores PARylation and counteracts PARP inhibitor-mediated synthetic lethality","volume":"35","author":"Gogola","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2026.110204_bb0125","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1002\/cam4.5062","article-title":"Hematological toxicities in PARP inhibitors: a real-world study using FDA adverse event reporting system (FAERS) database","volume":"12","author":"Shu","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.bioorg.2026.110204_bb0130","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood-2012-12-472845","article-title":"Parp-2 is required to maintain hematopoiesis following sublethal \u03b3-irradiation in mice","volume":"122","author":"Farr\u00e9s","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.110204_bb0135","doi-asserted-by":"crossref","first-page":"21717","DOI":"10.1021\/acs.jmedchem.4c01725","article-title":"Discovery of 6-fluoro-5-{4-[(5-fluoro-2-methyl-3-oxo-3,4-dihydroquinoxalin-6-yl)methyl]piperazin-1-yl}- N -methylpyridine-2-carboxamide (AZD9574): a CNS-penetrant, PARP1-selective inhibitor","volume":"67","author":"Johannes","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110204_bb0140","doi-asserted-by":"crossref","first-page":"14498","DOI":"10.1021\/acs.jmedchem.1c01012","article-title":"Discovery of 5-{4-[(7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}- N -methylpyridine-2-carboxamide (AZD5305): a PARP1\u2013DNA trapper with high selectivity for PARP1 over PARP2 and other PARPs","volume":"64","author":"Johannes","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110204_bb0145","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2505725","article-title":"Vepdegestrant, a PROTAC estrogen receptor degrader, in advanced breast cancer","volume":"393","author":"Campone","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2026.110204_bb0150","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12943-021-01434-3","article-title":"Proteolysis-targeting chimeras (PROTACs) in cancer therapy","volume":"21","author":"Li","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bioorg.2026.110204_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113091","article-title":"Discovery of selective CDK9 degraders with enhancing antiproliferative activity through PROTAC conversion","volume":"211","author":"Qiu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110204_bb0160","doi-asserted-by":"crossref","first-page":"17319","DOI":"10.1021\/acs.jmedchem.4c01223","article-title":"Discovery of novel PROTAC SIRT6 degraders with potent efficacy against hepatocellular carcinoma","volume":"67","author":"Huang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110204_bb0165","first-page":"1","article-title":"Safety considerations for cereblon-recruiting targeted protein degraders","author":"Garside","year":"2026","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2026.110204_bb0170","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41591-024-03434-4","article-title":"Artificial intelligence in drug development","volume":"31","author":"Zhang","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioorg.2026.110204_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.140125","article-title":"Discovery of novel thiophene [2,3-D] pyrimidine\u2013thiazole derivative as promising MNK inhibitor to treat breast cancer","volume":"1321","author":"Zhu","year":"2025","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2026.110204_bb0180","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.bmcl.2019.04.009","article-title":"Discovery of an EGFR tyrosine kinase inhibitor from ilex latifolia in breast cancer therapy","volume":"29","author":"Wang","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110204_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114860","article-title":"Discovery of novel hydroxyamidine based indoleamine 2,3-dioxygenase 1 (IDO1) and thioredoxin reductase 1 (TrxR1) dual inhibitors","volume":"245","author":"Zhou","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110204_bb0190","doi-asserted-by":"crossref","first-page":"4588","DOI":"10.1021\/acs.jmedchem.0c02044","article-title":"Structure-enabled discovery of novel macrocyclic inhibitors targeting glutaminase 1 allosteric binding site","volume":"64","author":"Xu","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110204_bb0195","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1039\/D2SC06860E","article-title":"Discovery of a photoactivatable dimerized STING agonist based on the benzo[b]selenophene scaffold","volume":"14","author":"Liu","year":"2023","journal-title":"Chem. Sci."},{"key":"10.1016\/j.bioorg.2026.110204_bb0200","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.1016\/j.molcel.2024.10.024","article-title":"PARP enzyme de novo synthesis of protein-free poly(ADP-ribose)","volume":"84","author":"Langelier","year":"2024","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bioorg.2026.110204_bb0205","doi-asserted-by":"crossref","first-page":"11012","DOI":"10.1021\/acs.jmedchem.0c00821","article-title":"Discovery of SK-575 as a highly potent and efficacious proteolysis-targeting chimera degrader of PARP1 for treating cancers","volume":"63","author":"Cao","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110204_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114846","article-title":"The SAR and action mechanisms of autophagy inhibitors that eliminate drug resistance","volume":"244","author":"Ye","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110204_bb0215","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.bmcl.2018.12.065","article-title":"Shape-based virtual screen for the discovery of novel CDK8 inhibitor chemotypes","volume":"29","author":"He","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110204_bb0220","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1021\/acs.jmedchem.3c01093","article-title":"Discovery of novel aminobutanoic acid-based ASCT2 inhibitors for the treatment of non-small-cell lung cancer","volume":"67","author":"Qin","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110204_bb0225","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1158\/1078-0432.CCR-10-0523","article-title":"Histone \u03b3H2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers","volume":"16","author":"Redon","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110204_bb0230","doi-asserted-by":"crossref","first-page":"13106","DOI":"10.1021\/acs.jmedchem.4c01017","article-title":"Structural and physicochemical features of oral PROTACs","volume":"67","author":"Schade","year":"2024","journal-title":"J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826007406?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826007406?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:36:34Z","timestamp":1787675794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826007406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":46,"alternative-id":["S0045206826007406"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110204","relation":{"is-supplemented-by":[{"id-type":"uri","id":"https:\/\/data.mendeley.com\/preview\/3n8hyf2mkr?a=6dca524d-68a6-4643-ba0c-d196ecc41a19","asserted-by":"subject"}]},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potent and isoform-selective PARP1 degraders for the treatment of BRCA-deficient cancers","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110204","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110204"}}